US Stock Market Closed

Dashboard

BioCryst Pharmaceuticals, Inc. (BCRX)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity

S

Analyst Opinion

B

Leverage & Liquidity

S

Fundamental Variables

H

Rating Performance

FV Performance

About

BioCryst Pharmaceuticals, Inc. designs and develops novel, oral and small-molecule medicines. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.

CEO

Jon P. Stonehouse

Employees

140

Industry

-

Sector

-

Headquarters

Durham

Exchange

NASDAQ

Summary Stats

Market Cap

1.89B

Revenue

188M

Net Income

-194M

EPS

-$1.07

Price-to-Earnings

-9.51

Price-to-Book

-11.49

Debt-to-Equity

-4.21

News

Analyst Ratings

Price targets projected by 9 analysts

High

$13.00

Average

$8.61

Low

$4.00

Ratings calculated by 10 analysts

Buy

8

Hold

2

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q1 2022

Last Earnings

Missed by -$0.03

Actual

-$0.40 -8.1%

Consensus

-0.37

Report Date

Year Ago

-0.36

Year Ago Change %

Down 11%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites